Aspira Association

Aspira Women's Health is a bio-analytical based women's health company focused on the development of innovative diagnostic tests for gynecologic diseases. The company specializes in AI-powered proteomic solutions, most notably its OvaSuite portfolio, which includes the FDA-cleared Ova1Plus and OvaWatch tests for assessing ovarian cancer risk in women with adnexal masses. By combining multiple serum biomarkers with proprietary algorithms, Aspira aims to improve the early detection of ovarian cancer and provide personalized risk assessment to guide clinical management. The company is also expanding its pipeline to include diagnostic solutions for endometriosis and other high-unmet-need areas in women's health.